Financial Performance - AYVAKIT revenue reached $149.4 million in Q1 2025, a 61% year-over-year growth[14] - The company is raising AYVAKIT revenue guidance for 2025 to $700 - $720 million[14] - Blueprint Medicines anticipates $2 billion in AYVAKIT revenue by 2030 and a $4 billion peak for the SM franchise[14] - The company maintains a strong cash position of approximately $900 million[14] AYVAKIT Commercial Performance - Ex-US AYVAKIT revenue was $83.1 million in Q1 2025[16] - US AYVAKIT revenue was $66.3 million in Q1 2025[16] - Approximately 75% of SM patients start AYVAKIT at a 25 mg dosage[17] - Over 95% of AYVAKIT patients strongly agree that they are satisfied with AYVAKIT as a treatment for their SM[26] Pipeline Development - Blueprint Medicines initiated BLU-808 proof-of-concept studies in ARC and CU[14] - The company is advancing enrollment in the registration-enabling HARBOR study of elenestinib in ISM[14]